Management
Read about our leadership team, Ribocure board and Science board below.
Menu
Read about our leadership team, Ribocure board and Science board below.
Dr. Li-ming Gan
Chief Executive Officer
MD, PhD
Dr. Anders Gabrielsen
VP and Head of Global Clinical Development
MD, PhD
Anders Gabrielsen, MD, DMSc, Associate Professor, is a physician scientist with 10+ years of industry experience across the CVRM therapy area. Cardiologist and Internist by training at Karolinska Institutet and Karolinska University Hospitals, with subspecialty in heart failure and core clinical team duties across all aspects of cardiology and internal medicine. Long-standing research experience with translational cardiovascular research focusing on heart failure, pathophysiology, translational vascular biology, atherosclerosis and inflammation with explorative studies including target ID and biomarker exploration studies. Extensive global pharma industry experience working with Bayer, Novartis and AstraZeneca covering multiple CVRM development MoA’s, indications and launches. In the latest role with AstraZeneca served as executive group director for early clinical development with responsibility for cardiovascular and heart failure project clinical activities.
Dr. Sara Svedlund
Head of Ribocure Clinic & Senior Medical Director
MD, PhD
Head of Ribocure Clinic, Ribocure Pharmaceuticals AB.
Sara Svedlund is chief physician and associate professor in non-invasive cardiology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg. Sara has 15 years of clinical experience as physician and is specialized in cardiovascular, exercise and pulmonary physiology. She was licensed physician in 2011 and defended her thesis the same year. Sara became a medical specialist in 2017 and was appointed associate professor in 2019. She was Care Unit Chief Physician at the Clinical Department for Cardiopulmonary Physiology at Sahlgrenska University Hospital during 2016-2022. Research wise, Sara has focused on clinical trials, development and validation of different methodological aspects as well as identification of mechanisms and biomarkers in different cardiovascular patient populations. Further, she has worked extensively with methodological alignment in clinical trials and run an academic echocardiography core lab between 2015-2022. Since March 2022 she is Head of Clinical Operations at Ribocure.
Rebeckha Magnusson
Head of Clinical Operations & Quality Assurance
Maria Liljevald
Head of Global Regulatory Affairs
BSc
Maria Liljevald holds a BSc in molecular biology at the University of Gothenburg and she has 20 years of experience in the pharmaceutical industry. She started her career at AstraZeneca as a lab-based molecular biologist in the transgenic research laboratory in 2004. She moved into preclinical Toxicology 2012. As a Global Toxicology Project Lead, Maria supported drug projects from pre-clinical up to Ph2b, covering various modalities such as oligos, small molecules and Fixed Dose Combination programs in a variety of therapeutic areas. Based on her expertise and experience, she has been on the European Register of Toxicologist (ERT) since 2019. In 2021 Maria took the role as Global Regulatory Lead supporting projects from pre-clinical into Ph2b. She has successfully steered projects through multiple INDs, global Ph2 clinical trial applications, and Health Authority interactions. Recently Maria took on a role as European Regulatory Affairs Lead for a project in the late stage of Ph3 preparing for MAA application. Maria joined Ribocure Pharmaceutical AB in June 2023 as Head of Global Regulatory Affairs.
Dr. Lotta Egnell
Global Head of DMPK & Clinical Pharmacology
MSc, PhD
Lotta (Ann-Charlotte) Egnell has extensive senior leadership experience in Clinical Pharmacology and DMPK with 20 years big pharma industry experience in the CVRM therapy area. Lotta is a pharmacist by training at Uppsala University, Sweden and holds a PhD in translational and computational modeling of atypical enzyme kinetics of drug metabolizing cytochrome P450s from the University of Manchester, UK. Lotta has led the implementation of model based preclinical drug discovery approaches within the CVRM research area at AstraZeneca, and more recently led a team of Clinical Pharmacology Scientists and Clinical Pharmacometricians, supporting a model based clinical development, impacting decision making from Ph1 up to life cycle management. Her project impact spans several different modalities, and from target selection to life cycle management. Lotta also holds a Master in Leadership and Organization, and has extensive line management as well as project leadership experience.
Dr. Johannes Wikström
Head of Bioscience and Global projects
MSc, PhD
Dr. Anna B Granqvist
Senior Project Director
MSc, PhD
Anna B Granqvist has a PhD in Renal medicine/physiology and experience both from working in Academia (15 years) and big pharma company (10 years at AstraZeneca).
She has a broad experience in pre-clinical models (in vitro and in vivo) and was the renal in vivo Team leader for several year supporting the renal strategy and pipeline build at AstraZeneca. She has been Project leader and principal investigator for both pipeline and technical platform projects as well as collaborations with both academic groups and biotech companies.
Dr. Julia Grönros
Project Director External Innovation
MSc, PhD
Julia Grönros holds a MSc in biology and a PhD in physiology at University of Gothenburg from 2008. She did her post doc at Karolinska Institute in a joint venture with AstraZeneca, Gothenburg. Her research interest is within cardiovascular diseases such as atherosclerosis and myocardial infarction, as well as type 2 diabetes. She has worked extensively with developing preclinical animal models for disease and for target validation, with an expertise in ultrasound imaging techniques. Before joining Ribocure, she worked seven years at the Grants and Innovation Office at University of Gothenburg, as responsible research coordinator in the establishment of a successful research Centre within translational and molecular medicine. Julia joined Ribocure in March 2022 as Project Director for External Innovation.
Pontus Boman
Head of Data Science & IT
MSc
Pontus has more than 30 years of experience from Pharmaceutical and Clinical Development. He has worked within the big pharma, small pharma, CRO, technology vendor and public health care sectors in various positions at AstraZeneca, VGR IT, Oncopeptides, Replior, TFS Health Science and Aixial Group. The focus during the last 20 years has been on biometrics, data science and computerized systems catalyzing clinical trials.
Pontus holds a M.Sc. in Chemical Engineering from Chalmers University of Technology, augmented with various university courses in data science, life science and quality management.
Dr. Felix Gnerlich
Head of Chemistry
Dipl. Chem., PhD
Felix is committed to advancing therapeutic oligonucleotides across various therapeutic areas. He has held key roles at renowned organizations in both the biotech and big pharma sectors.
Equipped with a PhD in organic and nucleic acid chemistry, he joined Sanofi’s Nucleic Acid Therapeutics Platform where he was leading a team specializing in synthesis of therapeutic siRNA and targeted delivery for systemic administration.
Transitioning to Rigontec, a clinical-stage biotech company, he spearheaded the chemistry R&D at the startup leveraging his expertise to implement oligonucleotide chemistry capabilities to develop immunostimulatory RNA as cancer drugs. This company was acquired by the US pharma company Merck, Sharp & Dohme in 2017.
Following this success, Felix ventured into AstraZeneca’s Respiratory & Immunology department aiming to establish oligonucleotide therapeutics for respiratory disease. Throughout his tenure, he played a pivotal role in establishing an early-stage pipeline for oligonucleotide drugs in respiratory diseases and helped enhancing the company’s oligonucleotide drug discovery capabilities.
In February 2024, Felix joined Ribocure as Head of Chemistry.
Malin Westberg
Business Planning Lead
Malin Westberg has over 30 years of experience from administrative roles within the pharmaceutical industry. Between 2016 and 2023, Malin was a Senior Administrator and Team Leader within Pharmaceutical Sciences at AstraZeneca. There, she tackled the challenges of recruitment, planning, and shaping of the newly created department, and working closely with the Head of Business Planning and Operations. Malin particularly excels at strategic partnering and business development.
John Taylor
VP Business Development
PhD
John is a Business Development leader and has worked across search & evaluation, due diligence & with transactions. He has an established track record of success concluding many in-licensing & out-licensing deals. He has a strong network across global pharma, biotech, and academic environments. John spent significant time at AstraZeneca in Business Development in Gothenburg. Before this a biology department head in AZ Lund, Sweden. John also spent ten years at Pfizer as a Project Leader. John has a Ph.D. for studies on DNA-protein recognition with Prof. Steve Halford (FRS) at Bristol. He then studied DNA mismatch repair with Prof. Paul Modrich (Nobel Laureate 2015) at Duke in the USA.
Anders Waas
Business Development Lead
Anders Waas
Business Development Lead
Dr. Li-ming Gan
Chief Executive Officer & Board member
MD, PhD
Dr. Zicai Liang
Chair of Board
PhD
Dr. Hongyan Zhang
Board member
PhD
Board member , Ribocure Pharmaceuticals AB President, Suzhou Ribo Life Science Co., Ltd.
Dr Hongyan Zhang is one of the co-founders of Suzhou Ribo Life Science Co., Ltd. Since 2007, she has been the Director of Suzhou Ribo Life Science Co., Ltd. responsible for the overall management and operations of the company. Dr. Hongyan Zhang has more than 20 years of experience in academia and biomedicine. She is an expert in small nucleic acid technology and has vast experience in the establishment and operation of biotechnology companies. Under her leadership, Suzhou Ribo Life Science Co., Ltd. has established a professional and efficient R&D department and from scratch, presided more than ten major new drugs to first time in man. Thereby the company realized the first small nucleic acid therapeutics platform in China. Suzhou Ribo Life Science Co., Ltd. has gathered and trained a large number of high-level professional researchers in small nucleic acid technology and pharmaceuticals, formed the largest innovative research and development platform involving the entire technology chain in Asia. Dr. Hongyan Zhang received her Ph.D. in molecular biology from Uppsala University in Sweden and did her postdoctoral research at Yale University School of Medicine in the United States.
Professor Lilach Lerman
Advisor renal diseases
MD, PhD
Lilach O. Lerman, MD, PhD, is the Arthur M. and Gladys D. Gray Professor of Medicine and of Physiology in the Mayo Medical School and the Mayo Graduate School. She is the Director of the Renovascular Research Laboratory, Head of the Nephrology Research Unit, and Director of the Regenerative Nephrology Section in the Division of Nephrology & Hypertension at Mayo Clinic. Prof. LO Lerman has been involved in translational nephrology and hypertension research for over 30 years, with a focus on renovascular disease, physiological imaging, the microcirculation, and regenerative medicine.
Professor Stefano Romeo
Advisor NASH and lipids
MD, PhD
Professor Amir Lerman
Advisor cardiovascular diseases
MD, PhD
Professor Stephane Heymans
Advisor cardiomyopathies
MD, PhD
Ribocure will be expanding heavily in Sweden and looking for new talents to join, and academic associations as well as small and large enterprise partners to collaborate with, with the joint goal of developing highly differentiated and innovative oligonucleotide therapeutics to help patients in need.
Sitemap
About Ribocure
Contact us
